Accession Number : AD1007755


Title :   ETS-Associated Genomic Alterations including ETS2 Loss Markedly Affect Prostate Cancer Progression


Descriptive Note : Technical Report,30 Sep 2013,29 Sep 2015


Corporate Author : Memorial Sloan Kettering Cancer Center New York United States


Personal Author(s) : Bose,Rohit


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1007755.pdf


Report Date : 01 Oct 2015


Pagination or Media Count : 14


Abstract : Prostate cancer is the most common cancer in men, and the second-most common cause of cancer related death in the United States. Despite recent medical advances, once this cancer manifests beyond the confines of the prostate, most commonly in the bones and spine, it is incurable and can cause significant suffering prior to death. Current investigations study the molecular and genetic basis of the disease, to identify potential new drug targets and therapies. Approximately half of all prostate cancers contain a fusion between two genes,TMPRSS2 and ERG, and a further half of these contain a deletion of the 14 genes lying between TMPRSS2 and ERG. I have now performed a screen involving inhibition of each of these 14 genes, and am currently validating whether one or more of these genes does indeed affect cellular proliferation in vitro and in vivo.


Descriptors :   prostate cancer , drugs , therapy , genes , metastasis


Distribution Statement : APPROVED FOR PUBLIC RELEASE